Prevention of microvascular complications in diabetic children and adolescents

被引:3
|
作者
Verrotti, A [1 ]
Catino, M [1 ]
Di Ricco, L [1 ]
Casani, A [1 ]
Chiarelli, F [1 ]
机构
[1] Univ G dAnnunzio, Osped Policlin, Dept Pediat, I-66100 Chieti, Italy
关键词
diabetes; microvascular complications; nephropathy; retinopathy;
D O I
10.1111/j.1651-2227.1999.tb14338.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Diabetes mellitus causes profound alterations in many body tissues. Microvascular diabetic complications include diabetic neuropathy, nephropathy and retinopathy. Nephropathy first becomes manifest with hyperfiltration and microalbuminuria. These functional changes evolve over several years to a stage of marked deterioration of renal function. The possible preventive measures are metabolic control, reduction of dietary protein intake and use of ACE-inhibitors. Metabolic control is also important for the prevention of diabetic retinopathy. In fact, patients with HbA1c higher than 10% have an increased risk of progression of retinopathy. Moreover, an accelerated progression of retinopathy has been observed in patients with systemic hypertension following the onset of microalbuminuria. It has been demonstrated that diabetic neuropathy can also be present during childhood; therefore, it is possible to detect electrophysiological abnormalities in children and adolescents with IDDM. Glycaemic and blood pressure control are, so far, the main means for possible prevention or modification of the natural history of diabetic microvascular complications. Tight glycaemic control may have beneficial effects for diabetic neuropathy. In addition, other preventive measures, such as aldose reductase inhibitors, gangliosides, neurotrophic vitamins, etc., have been studied in the last years. However, no conclusive results have been obtained so far.
引用
收藏
页码:35 / 38
页数:4
相关论文
共 50 条
  • [41] PREVENTION OF DIABETIC FOOT COMPLICATIONS
    LITZELMAN, DK
    SLEMENDA, CW
    LANGEFELD, CD
    VINICOR, F
    CLINICAL RESEARCH, 1990, 38 (02): : A717 - A717
  • [42] PREVENTION AND TREATMENT OF DIABETIC COMPLICATIONS
    LEVIN, ME
    BONIUK, I
    ANDERSON, CB
    AVIOLI, LV
    ARCHIVES OF INTERNAL MEDICINE, 1980, 140 (05) : 691 - 696
  • [43] Unlocking the biology of RAGE in diabetic microvascular complications
    Manigrasso, Michaele B.
    Juranek, Judyta
    Ramasamy, Ravichandran
    Schmidt, Ann Marie
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2014, 25 (01): : 15 - 22
  • [44] The emerging role of dyslipidemia in diabetic microvascular complications
    Savelieff, Masha G.
    Callaghan, Brian C.
    Feldman, Eva L.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2020, 27 (02) : 115 - 123
  • [45] The Prevalence of Diabetic Microvascular Complications in China and the USA
    Lin, Yu Kuei
    Gao, Bixia
    Liu, Lili
    Ang, Lynn
    Mizokami-Stout, Kara
    Pop-Busui, Rodica
    Zhang, Luxia
    CURRENT DIABETES REPORTS, 2021, 21 (06)
  • [46] Cystic fibrosis: prevalence of microvascular diabetic complications
    Andersen, HU
    Lanng, S
    Pressler, T
    Laugesen, C
    Mathiesen, ER
    DIABETOLOGIA, 2005, 48 : A344 - A344
  • [47] Strict glycemic control and diabetic microvascular complications
    Shichiri, M
    INTERNAL MEDICINE, 1997, 36 (02) : 144 - 147
  • [48] Nanoformulations of flavonoids for diabetes and microvascular diabetic complications
    Agarawal, Kopal
    Kulkarni, Yogesh Anant
    Wairkar, Sarika
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2023, 13 (01) : 18 - 36
  • [49] The Prevalence of Diabetic Microvascular Complications in China and the USA
    Yu Kuei Lin
    Bixia Gao
    Lili Liu
    Lynn Ang
    Kara Mizokami-Stout
    Rodica Pop-Busui
    Luxia Zhang
    Current Diabetes Reports, 2021, 21
  • [50] Nanoformulations of flavonoids for diabetes and microvascular diabetic complications
    Kopal Agarawal
    Yogesh Anant Kulkarni
    Sarika Wairkar
    Drug Delivery and Translational Research, 2023, 13 : 18 - 36